Leu-AMS, a leucine analogue and potent inhibitor of leucyl-tRNAsynthetase (LRS) with an IC50 of 22.34 nM, exhibits cytotoxic effects in both cancer and normal cells and hampers bacterial growth. It specifically inhibits LRS's catalytic activity without impacting the leucine-induced activation of mTORC1.
DS86760016 is a highly effective inhibitor of leucyl-tRNAsynthetase (LeuRS), demonstrating potent activity against multidrug-resistant (MDR) Gram-negative bacteria including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Notably, DS86760016 effectively inhibits LeuRS enzymes derived from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, exhibiting IC50 values of 0.38 μM, 0.62 μM, and 0.16 μM, respectively.
Epetraborole is a potent and selective leucyl-tRNAsynthetase inhibitor. Epetraborole was in development for the treatment of infections caused by multidrug-resistant Gram-negative pathogens.